Related papers: A Systemic Pathological Network Model and Combinat…
Alzheimer's disease (AD) persists as a paramount challenge in neurological research, characterized by the pathological hallmarks of amyloid-beta (Abeta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau. This review…
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by the accumulation of amyloid-beta (A$\beta$) and phosphorylated tau (p-tau) proteins, leading to cognitive decline measured by the Alzheimer's Disease…
Alzheimers Disease (AD) is a progressive neurodegenerative disorder that poses significant challenges in its early diagnosis, often leading to delayed treatment and poorer outcomes for patients. Traditional diagnostic methods, typically…
Currently, many studies of Alzheimer's disease (AD) are investigating the neurobiological factors behind the acquisition of beta-amyloid (A), pathologic tau (T), and neurodegeneration ([N]) biomarkers from neuroimages. However, a…
Background: Despite the striking efforts in investigating neurobiological factors behind the acquisition of amyloid-\b{eta} (A), protein tau (T), and neurodegeneration ([N]) biomarkers, the mechanistic pathways of how AT[N] biomarkers…
Alzheimer's disease (AD) is a heterogeneous, multifactorial neurodegenerative disorder characterized by beta-amyloid, pathologic tau, and neurodegeneration. There are no effective treatments for Alzheimer's disease at a late stage, urging…
Alzheimer's Disease (AD) is a complex neurodegenerative disorder marked by memory loss, executive dysfunction, and personality changes. Early diagnosis is challenging due to subtle symptoms and varied presentations, often leading to…
Alzheimer's disease (AD) is an age-specific neurodegenerative disease that compromises cognitive functioning and impacts the quality of life of an individual. Pathologically, AD is characterised by abnormal accumulation of beta-amyloid…
Mathematical modeling offers a valuable approach to understanding Alzheimers disease (AD) given its complexity, unknown causes, and lack of effective treatments. Models, once validated, offer a powerful tool to test medical hypotheses that…
Alzheimer's Disease (AD) is an irreversible neurodegenerative disease characterized by progressive cognitive decline as its main symptom. In the research field of deep learning-assisted diagnosis of AD, traditional convolutional neural…
Three major biomarkers: beta-amyloid (A), pathologic tau (T), and neurodegeneration (N), are recognized as valid proxies for neuropathologic changes of Alzheimer's disease. While there are extensive studies on cerebrospinal fluids…
Alzheimer's disease (AD) is a neurodegenerative disorder that is beginning with amyloidosis, followed by neuronal loss and deterioration in structure, function, and cognition. The accumulation of amyloid-beta in the brain, measured through…
The preclinical stage of many neurodegenerative diseases can span decades before symptoms become apparent. Understanding the sequence of preclinical biomarker changes provides a critical opportunity for early diagnosis and effective…
Alzheimer's disease (AD) is driven by the accumulation of amyloid-beta (Abeta) proteins in the brain, leading to memory loss and cognitive decline. While monoclonal antibodies targeting Abetahave been approved, optimizing their use to…
Machine learning approaches for Alzheimer's disease (AD) diagnosis face a fundamental challenges. Clinical assessments are expensive and invasive, leaving ground truth labels available for only a fraction of neuroimaging datasets. We…
Unveiling pathological brain changes associated with Alzheimer's disease (AD) is a challenging task especially that people do not show symptoms of dementia until it is late. Over the past years, neuroimaging techniques paved the way for…
Alzheimer s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, where early detection is essential for timely intervention and improved patient outcomes. Traditional diagnostic methods are…
Alzheimer's Disease (AD) is marked by significant inter-individual variability in its progression, complicating accurate prognosis and personalized care planning. This heterogeneity underscores the critical need for predictive models…
Understanding the molecular-level mechanisms underpinning Alzheimer's disease (AD) by studying crucial genes associated with the disease remains a challenge. Alzheimer's, being a multifactorial disease, requires understanding the gene-gene…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that severely impairs survival and quality of life. While anti-amyloid beta (Abeta) therapies can slow disease progression, their efficacy depends on personalized dosing…